Chalmers Don, Nicol Dianne
University of Tasmania, Australia.
J Law Med. 2008 Feb;15(4):538-55.
This article examines international best practice for the establishment, maintenance and use of human genetic research databases (HGRDs), particularly focusing on large-scale population biobanks, and considers the measures that should be taken in Australia to comply with this best practice. These HGRDs play a pivotal role in basic research aimed at understanding the basis of human disease at the genetic level, and applied research aimed at putting that basic knowledge into practical application. In particular, the large-scale biobanks are vital research tools in the drive to uncover the causes and consequences of human health and disease. Biobanks are being established at regional, national and international levels throughout the world. Although their governance structures are uniformly complex, some best practices are emerging with regard to consent (particularly consent to future research and withdrawal of consent), privacy and data protection and intellectual property ownership and access. Best practices with regard to benefit-sharing are emerging much more slowly. This article reviews these international best practices with the aim of providing guidance for the development of appropriate regulatory structures in Australia.
本文探讨了建立、维护和使用人类遗传研究数据库(HGRD)的国际最佳实践,尤其关注大规模人群生物样本库,并考虑了澳大利亚为遵守这一最佳实践应采取的措施。这些人类遗传研究数据库在旨在从基因层面理解人类疾病基础的基础研究以及旨在将该基础知识付诸实际应用的应用研究中发挥着关键作用。特别是,大规模生物样本库是推动揭示人类健康与疾病的成因及后果的重要研究工具。世界各地正在区域、国家和国际层面建立生物样本库。尽管其治理结构普遍复杂,但在同意(特别是对未来研究的同意和撤回同意)、隐私和数据保护以及知识产权所有权和获取方面正出现一些最佳实践。关于利益分享的最佳实践出现得要慢得多。本文回顾这些国际最佳实践,旨在为澳大利亚制定适当的监管结构提供指导。